OMCL

OmnicellA

Nasdaq / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$58.00

+38.5% vs current

Most likely

Base case

45%

Probability

Target price

$51.00

+21.7% vs current

B-

Bear case

25%

Probability

Target price

$38.00

-9.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-06

AI commentary

Recent coverage was dominated by the April 28 earnings release and generally carried a positive tone around the return to profitability and raised 2026 profitability guidance. Still, the evidence set is closer to a monitoring-style post-print memo than a fully broadened thesis refresh because social coverage is absent, analyst-revision detail is limited, and forward visibility still depends on hospital adoption timing for Titan XT and OmniSphere.

RankAlpha Sentiment Codex - 2026-05-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-28eventQ1 profitability step-up and raised full-year profitability guideHigh impact

Omnicell reported Q1 2026 revenue of $310 million, up 15% year over year, with GAAP EPS of $0.25, non-GAAP EPS of $0.55, non-GAAP EBITDA of $45 million, and raised full-year 2026 non-GAAP EBITDA and non-GAAP EPS guidance after what management described as strong execution and spend discipline [#8-K-2026-04-28].

2026-08-04catalystQ2 execution checkpoint against tightened profitability expectationsHigh impact

Company guidance calls for Q2 2026 revenue of $307 million to $313 million, non-GAAP EBITDA of $37 million to $42 million, and non-GAAP EPS of $0.40 to $0.48, making the next quarterly print a near-term confirmation test for whether margin gains and product demand are durable [#8-K-2026-04-28].

2027-05-06catalystTitan XT and OmniSphere adoption can extend the growth runwayHigh impact

Management said customer engagement is underway for Titan XT while health systems begin incorporating the platform into longer-term capital planning cycles, and the 10-K frames OmniSphere as the enterprise intelligence layer intended to unify hardware and software across medication management workflows [#8-K-2026-04-28] [#10-K-2026-02-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-06 • Updated nightlySource: Internal modelMethodology